Group 1: Research Basic Information - The research object is Leguo Co., Ltd., belonging to the household light industry, and the reception time was on October 24, 2025. The listed company's reception staff included the board secretary Yu Haoying and the securities affairs representative Qu Qilong [16] Group 2: Detailed Research Institutions - The research institutions included fund management companies (Huaxia, Guangdong Zhengyuan Private Equity, Huisheng, etc.), asset management companies (Qingrong, Yangtze River Securities (Shanghai)), investment companies (Guangdong Yuancheng Private Securities Investment, Shenzhen Hunt Investment Capital), securities companies (Guoxin Securities, Tianfeng Securities, Shanghai Securities, etc.), insurance asset management companies (China Life, Pacific), and others (Development Research Center, Guangdong Hengjian) [17][18][19] Group 3: Main Content Overseas Warehouse - In Q3, the gross profit margin of the company's overseas warehouse business was basically flat quarter - on - quarter. The current average utilization rate of overseas warehouses exceeded 70%, and the profitability of new non - US warehouses in Germany, the UK, and Canada had been continuously improving. The company will continue to invest in automation and informatization to improve storage operation efficiency and cost control capabilities [24] - As of the end of September 2025, the company had 19 self - operated overseas warehouses globally, with a total area of 650,000 square meters. The revenue of the overseas warehouse segment maintained a high growth rate. In the first three quarters, it had served 1,932 overseas enterprises, and the parcel volume increased by over 100% year - on - year. In the future, with the commissioning of self - built warehouses, the scale effect will gradually appear, and the profit margin is expected to further increase [26] US Terminal Demand under Sino - US Tariff Disturbance - The uncertainty in the Sino - US trade environment remains high. For optional consumer goods and products in offline supermarket channels, tariff adjustments and cost increases have led to price hikes, affecting the sales volume of OEM customers and putting periodic pressure on the company's OEM business. However, cross - border e - commerce has maintained steady growth, with the core category of intelligent lifting desks stable and rising, and the revenue of electric sofas and ergonomic chairs increasing significantly. It is expected that with the Fed entering the interest - rate cut cycle, consumer confidence will be boosted [25] OEM Business Development Trend - Affected by tariff policy adjustments, the offline supermarket OEM business is facing certain pressure on price transmission and sales volume. The company expects this business to gradually recover after the industry demand stabilizes. Meanwhile, the company is actively expanding emerging markets in Asia, Africa, and Latin America through brand agency and cooperation models to disperse trade risks and cultivate new performance growth points [25][26] Cross - border E - commerce Business - During the reporting period, the company's cross - border e - commerce business maintained steady growth. The sales revenue of independent websites accounted for over 40% of the total cross - border e - commerce revenue, with a year - on - year increase of about 12%. Independent websites have significant advantages in new product promotion, scenario - based marketing, and brand building. The Amazon channel has intense industry competition and obvious price involution. The company will continue to strengthen brand differentiation positioning and product innovation capabilities [27]

Report Summary 1. Reported Industry Investment Rating Not provided in the given content. 2. Core Viewpoints of the Report - The company will continue to focus on the field of allergic disease diagnosis and treatment and optimize its sales management system [31]. - In marketing, the company will increase resource investment, adhere to academic promotion, and promote the sustainable growth of allergen product revenue [31]. - In R & D, the company promotes product layout from a full - life - cycle perspective, and all work is carried out in an orderly manner while effectively controlling R & D expenditures [32]. - The company will continue to optimize details and improve energy efficiency in operation and internal control management to ensure overall stable operation and strive to improve performance in the future [32]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - Research object: Iwu Biological [16] - Industry: Biological products [16] - Reception time: October 24, 2025 [16] - Listed company reception personnel: Chairman Hu Gengxi, General Manager He Jianming, Deputy General Manager and Board Secretary Guan Zhenwei [16] 3.2. Detailed Research Institutions -证券公司: Zhongtai Securities, Kaiyuan Securities, Zhongyou Securities, CITIC Securities, Shenwan Hongyuan Securities, Guotai Haitong Securities, Xingye Securities, Huayuan Securities, Guosheng Securities, Orient Securities, Guoxin Securities, Huatai Securities Shanghai [17][18][19] -基金管理公司: China Merchants Fund, Dacheng Fund, BOC Fund, China - Europe Fund, Jishi Fund, Tianzhi Fund, Shenwan Lingxin Fund, Guolianan Fund, Chuangjin Hexin Fund, Ping An Fund, Tongtai Fund, Hongta Hongtu Fund, Changxin Fund, Huaan Fund, F安达 Fund, Jiaoyin Schroeder Fund, Huatai Berry Fund, Xinda Australia Asia Fund, Noah Fund, Shanghai Hexi Private Fund, Guangdong Huizheng Private Fund [17][18][19][20] -资产管理公司: Shanghai Zhaowan, BOC Asset Management, CITIC Asset Management, Shanghai Zhongyu, Caitong Securities, Shanghai Shifeng, Shanghai Mingyu, Gefei [17][18][19][20] 3.3. Research Institution Proportion Not provided in the given content. 3.4. Main Content Data 3.4.1. Business Situation Introduction - **Operating performance**: From January to September 2025, the company's operating income was 853,360,357.81 yuan, a year - on - year increase of 16.86%, and the net profit attributable to shareholders of the listed company was 344,866,533.27 yuan, a year - on - year increase of 26.67% [27]. - **Product sales**: From January to September 2025, the sales revenue of "Dust Mite Drops" was 794,221,951.72 yuan, a year - on - year increase of 13.38%; the sales revenue of "Artemisia annua Pollen Allergen Sublingual Drops" was 44,756,599.93 yuan, a year - on - year increase of 117.58%; the sales revenue of skin prick solution was 11,046,360.42 yuan, a year - on - year increase of 94.10% [27]. - **Profit distribution**: The company plans to distribute cash dividends of 1.00 yuan per 10 shares (tax - included) based on the total share capital of 523,584,000 shares. The plan needs to be reviewed and approved by the company's shareholders' meeting [27]. - **R & D pipeline**: In July 2025, "Artemisia annua Pollen Allergen Sublingual Drops" obtained a post - marketing clinical trial summary report; in August 2025, "Dermatitis Diagnostic Patch 02" entered Phase I clinical trials; in September 2025, "Aspergillus fumigatus Prick Solution" obtained a Phase I clinical trial summary report [28]. 3.4.2. Q&A Session - **Sales system management**: Since the second half of last year, the company has allocated more resources to sales and marketing, appointed backbone personnel, and adjusted the market area analysis and structure to improve management efficiency [28]. - **Competition pattern**: The company is not worried about competition from Changchun Hi - Tech's cooperation. More enterprises participating in the desensitization market can promote academic promotion and market education [29]. - **R & D progress**: The "House Dust Mite Film" is in Phase I clinical trials; "Dermatitis Diagnostic Patch 01" is in Phase II clinical trials; "Dermatitis Diagnostic Patch 02" is in Phase I clinical trials. Allogeneic mesenchymal stem cell therapy drugs and new anti - drug - resistant tuberculosis small - molecule drugs are in pre - clinical research [29]. - **Pricing of allergen skin prick test**: In June 2025, the National Healthcare Security Administration stipulated that different allergens in the allergen skin test fee can be charged in superposition. Specific prices vary by region [29]. - **Advantages of "House Dust Mite Film"**: It has good sublingual adsorption, better dosing accuracy, and better patient compliance [30]. - **Expense ratio**: The company's expenses from January to September 2025 can be found in the 2025 Q3 report, and the investment in expenses is dynamically planned and allocated according to business [30]. - **Sales of "Artemisia annua Pollen Allergen Sublingual Drops"**: From January to September 2025, the sales revenue was 44,756,599.93 yuan, a year - on - year increase of 117.58%, driven by academic promotion, increased awareness, and post - marketing clinical trials [31]. - **Recommendation in guidelines**: Sublingual desensitization therapy is recommended as a first - line treatment for allergic rhinitis and asthma in relevant domestic guidelines [31].

1. Report Industry Investment Rating - No information provided 2. Core View of the Report - The company actively seized the opportunities of manufacturing recovery and industrial chain reconstruction in H1 2025, achieving a year - on - year increase of 26.48% in operating income to 519.1076 million yuan, a year - on - year increase of 18.80% in net profit attributable to the parent company to 85.4597 million yuan, and a year - on - year increase of 18.32% in net profit attributable to the parent company after deducting non - recurring gains and losses to 83.8351 million yuan [24]. - The company will adhere to the development strategy of "independent R & D, continuous innovation", further strengthen its advantages in technology and product development, and develop new products. It will expand into new material fields and tool system fields to become a leading domestic overall cutting solution provider [24][25]. - The company is a well - known domestic carbide cutting tool manufacturer with its carbide CNC blade production ranking among the top in the domestic industry for many years. Its core products have entered the domestic mid - to - high - end market and have won many awards [26]. 3. Summary by Relevant Catalogs 3.1. Research Basic Situation - Research object: Huarui Precision [17]. - Industry: General equipment [17]. - Reception time: October 21, 2025 [17]. - Listed company reception personnel: Board secretary and CFO Duan Yanlan, securities affairs representative Yao Tianzong [17]. 3.2. Detailed Research Institutions - Guangdong Cheese Investment Fund Co., Ltd. (investment company) [18]. - Guolian (fund management company) [18]. - Huafu Securities (securities company) [18]. 3.3. Research Institution Proportion - No information provided 3.4. Main Content Data - **2025 H1 Performance**: Operating income was 519.1076 million yuan, up 26.48% year - on - year; net profit attributable to the parent company was 85.4597 million yuan, up 18.80% year - on - year; net profit attributable to the parent company after deducting non - recurring gains and losses was 83.8351 million yuan, up 18.32% year - on - year [24]. - **2025 H1 Sales Expenses**: 18.2125 million yuan, a year - on - year decrease of 1.98% mainly due to the decrease in share - based payment expenses [24]. - **2025 H1 Management Expenses**: 16.5805 million yuan, a year - on - year decrease of 8.77% mainly due to the decrease in share - based payment expenses [24]. - **Future Development Trend**: The company will strengthen R & D and talent building, expand into new material fields such as cermet, ceramic, and super - hard materials, and tool system fields to become a leading overall cutting solution provider [24][25]. - **Industry Status**: A well - known domestic carbide cutting tool manufacturer with its carbide CNC blade production ranking among the top in the domestic industry for many years. Its core products have entered the mid - to - high - end market and won many awards [26].

Group 1: Research Basic Information - The research object is Yangguang Nuoyue, belonging to the medical service industry, and the reception time is October 21, 2025 [17] - The listed company's reception staff includes the chairman, general manager, financial director, board secretary of Yangguang Nuoyue, the general manager of Langyan Life, and relevant personnel from the independent financial advisor and accounting firm [17] Group 2: Detailed Research Institutions - The reception objects include investors and others, and the reception object type is not clearly stated [20] Group 3: Research Institution Proportion - No specific content provided Group 4: Main Content Data - The company held an online performance briefing at the Shanghai Stock Exchange Roadshow Center, including management speeches and answering investor questions [24] - The significance of the reorganization for the company to improve its operating conditions: achieving industrial layout upgrade, significant synergy, accelerated strategic transformation, and dual improvement in performance and finance [24] - The company's long - term strategic positioning is to build a "R & D service + pipeline cultivation + new quality industrial chain" trinity business ecosystem and become an influential innovative drug R & D service enterprise [25] - Measures to improve company management and performance: perfecting performance appraisal indicators, deepening business structure upgrade, and using AI to empower R & D efficiency [25]

Report Summary 1. Report Industry Investment Rating - Not provided in the document 2. Core Viewpoint of the Report - Guangbo Co., Ltd. has achieved business transformation and continuous development from stationery to cultural and creative products, and then to trendy toys, creating new performance growth points [25] 3. Summary by Relevant Catalogs 3.1. Research Basic Information - Research object: Guangbo Co., Ltd. [17] - Industry: Household light industry [17] - Reception time: October 21, 2025 [17] - Company reception staff: Jiang Shuying, the board secretary and deputy general manager, and Wang Xiuna, the securities affairs representative [17] 3.2. Detailed Research Institutions - Reception object type: Securities company [20] - Institution: Southwest Securities [20] - Relevant personnel: Gou Yurui, Cai Xin, Shen Qi [20] 3.3. Research Institution Proportion - Not provided in the document 3.4. Main Content Information - **Company product exhibition**: The company introduced its products in the company showroom [22] - **IP matrix construction**: In the cultural and creative field, the company has launched sub - brands such as "kinbor", "fizz 飞兹", "papiest 派乐时刻", and strengthened IP resource introduction and cooperation, achieving a preliminary transformation from a traditional stationery manufacturer to a cultural and creative enterprise [23] - **Entry into the trendy toy field**: The company has accelerated the incubation of trendy toy categories, built an extreme single - product matrix, and implemented a strategy of coordinated development of head IPs and long - tail IPs to promote the development of trendy toy business [24] - **Exhibition products**: The company's trendy toy brand product matrix includes various categories. The exhibits at the CTE China Toy Fair & Trendy Toy Fair include co - branded products of many IPs, and the "Detective Conan M28: One - Eyed Remnant Image" food toy series was premiered [25] - **Overseas business**: The company is pushing forward overseas layout, targeting the Southeast Asian market, and promoting the large - scale export of products. It currently has production bases in Vietnam, Cambodia, and Malaysia and will expand the Vietnam production base [26]

Group 1: Report Overview - Report research object: Veli Medical, a company in the medical device industry [2][16] - Research date: October 21, 2025 [1][16] - Companies participating in the research: CITIC Futures, Yong'an Guofu, Zhongtai Medicine, Galaxy, Boyuan, etc. [2] Group 2: Core Views - From January to September 2025, the company achieved an operating revenue of 1.191 billion yuan, a year - on - year increase of 12.33%, and a net profit attributable to shareholders of the parent company of 192 million yuan, a year - on - year increase of 14.94%. The net profit after deducting non - recurring gains and losses attributable to shareholders of the parent company was 184 million yuan, a year - on - year increase of 15.22%. In Q3 2025, the company achieved an operating income of 446 million yuan, a year - on - year increase of 16.09%, a net profit attributable to shareholders of the parent company of 71 million yuan, a year - on - year increase of 16.31%, and a net profit after deducting non - recurring gains and losses attributable to shareholders of the parent company of 67 million yuan, a year - on - year increase of 13.17% [28] - The company will continue to be market - oriented, closely follow clinical needs, increase R & D investment, and accelerate the R & D of new products. It will also promote the rapid listing of more innovative products, accelerate the construction of the Indonesian factory overseas, and actively promote the overseas localization process [28] - The Indonesian factory is in the construction and pre - certification stage of products, and is expected to start shipping gradually by the end of Q1 2026. The first - phase production capacity will mainly supply large US customers, producing catheters and suction connecting tubes, and may add anesthetic products later. After the Indonesian factory is put into operation, it is expected to have a positive impact on the growth of the company's export orders [28] - The company will determine the ex - factory price of products from the overseas factory through negotiation with customers while maintaining the original product gross profit margin. It is expected that overseas production will not have a significant impact on the product gross profit margin [29] - The proportion of the company's high - margin products in overall operating income has exceeded 20% and is expected to further increase. Since 2023, the company has increased the export of urological products, and the export revenue of urological products has grown rapidly in the past two years. With the implementation of customized projects for overseas large customers, the product structure of overseas business has been optimized, and the proportion of high - margin products has increased [30] - The company's R & D products are mainly high - value - added and high - margin products. With the launch of new products, the company's product and business structure will be further optimized, and the proportion of high - margin products is expected to continue to increase [31] Group 3: Detailed Information by Section 1. Basic Research Information - Research object: Veli Medical [16] - Industry: Medical devices [16] - Reception time: October 21, 2025 [16] - Company reception personnel: Deputy General Manager and Secretary of the Board Chen Bin, Chief Financial Officer Zhu Yimin, and Securities Affairs Representative Wu Lifang [16] 2. Detailed Research Institutions - Institutions include futures brokerage companies (CITIC Futures), asset management companies (Yong'an Guofu, Mingyu Assets, etc.), other types (Zhongtai Medicine, etc.), fund management companies (Galaxy, Boyuan, etc.), insurance asset management companies (Taikang, etc.), and investment companies (Shenzhen Guoyin Capital, Zhuhai Shangshi, etc.) [17] 3. Research Institution Proportion - No relevant content provided 4. Main Content Materials - 2025 Q3 operating results: As mentioned above, showing growth in revenue and profit [28] - Indonesian factory: Construction progress, product supply, and expected impact on export orders and gross profit margin [28][29] - High - margin products: Current proportion, growth trends, and future expectations [30][31]

1. Report Industry Investment Rating - No information provided in the given content 2. Core View of the Report - In the first three quarters of 2025, the company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The company is optimistic about the development of the PEEK industry chain, and the production and market expansion of cosmetic raw material HAP are progressing normally. The company's product毛利率 has rebounded due to increased capacity utilization and decreased raw material prices [25][27][30] 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Xinhan New Materials, belonging to the chemical raw material industry. The reception time was on October 21, 2025, and the listed company's reception staff included the board secretary Li Xiangfei, the financial director Wang Zhongyan, and the securities affairs representative Ge Mingmin [16] 3.2 Detailed Research Institutions - The research institutions include fund management companies such as Baoying Fund, Chuangjin Hexin Fund, and Xinda Australia Asia Fund; investment companies like Dingtian Investment and Ruiyi Investment; securities companies such as Shenwan Hongyuan and CITIC Construction Investment Securities; other institutions including Marco Polo China Assets and Hongyun Private Equity Fund; and banks such as Ping An Bank [17][18] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **2025 Q1 - Q3 Brief Analysis**: The company achieved an operating income of 330 million yuan, a year - on - year increase of 7.99%, and a net profit of 51.53 million yuan, a year - on - year increase of 23.32%. The comprehensive gross profit margin and sales net profit margin of products gradually improved. The sales of the main products included 40% of DFBP, 18% of photoinitiators, 22% of cosmetic raw materials, and about 20% of medical and agricultural intermediates [25] - **Question and Answer Session**: - **DFBP**: The product price is adjusted periodically according to raw material prices and other factors and is currently at a low level. The production mainly comes from new capacity, with high capacity utilization and gradually repaired gross profit margin [26] - **PEEK**: It has excellent comprehensive performance, and new attempts in high - end manufacturing fields have added new growth momentum. The company is optimistic about the development of the PEEK industry chain [27][28] - **Cosmetic Raw Material HAP**: The production and market expansion are progressing normally, and the sales volume growth is due to the development of new customers and increased penetration. The product price is adjusted periodically [28] - **Three - Workshop of the Fund - Raising Project**: The equipment is being installed and is expected to be completed by December 2025 [29] - **Reasons for Gross Profit Margin Rebound in Q1 - Q3**: The continuous and stable increase in capacity utilization reduces the fixed cost per unit product, and the raw material price has decreased [30]

Report Overview - Reported Company: Qinchuan Wulian - Industry: Instrumentation - Research Date: October 21, 2025 [1][2][17] Report's Core View - The company's performance in Q3 2025 improved, with increased revenue, reduced losses, and improved cash flow The smart sensor business and overseas market are expected to drive future growth The company will continue to increase revenue through various measures and strengthen cost control and internal management [29][30] Key Points by Section 1. Research Basic Information - Research Object: Qinchuan Wulian - Industry: Instrumentation - Reception Time: 2025-10-21 - Reception Personnel: Chairman and General Manager Shao Zehua, Director and Deputy General Manager Li Yong, Board Secretary and Financial Controller Li Ting, Independent Director Liao Weizhi [17] 2. Detailed Research Institutions - The reception objects include investors and others [20] 3. Main Content R & D Investment - In January - September 2025, the R & D expense was 42.4095 million yuan, accounting for 19.36% of the revenue The company invested in R & D in smart city IoT, intelligent sensors, and industrial IoT, and obtained 197 new invention patents, 27 software copyrights, and participated in compiling 12 national standards from January to September 2025 As of September 30, 2025, the company had a total of 890 invention patents, 369 software copyrights, and participated in compiling 72 national standards [24] Overseas Business - From January to September 2025, the overseas revenue was 29.3623 million yuan, a year - on - year increase of 21.3771 million yuan (267.71%) The company will continue to focus on the markets in South America, Southeast Asia, and the Middle East [25][26] Performance Growth Drivers - The intelligent sensor business will be driven by policies and market demand, especially in the automotive, home appliance, and low - altitude economy fields The overseas market for gas meters also has growth potential [26][27] Domestic Gas Meter Business - In Q3 2025, the IoT smart gas meter business revenue was 54.8568 million yuan, a year - on - year increase of 6.95% The company will focus on large and medium - sized gas group customers and strengthen cost control [27] Cash Flow - In Q3 2025, the net cash flow from operating activities was 33.0952 million yuan, a year - on - year increase of 23.2604 million yuan, mainly due to better customer payments The company will continue to increase revenue and strengthen accounts receivable management [27][29] Cost Control and Profitability - In Q3 2025, the revenue and gross profit margin increased The company will integrate supply chain resources, optimize procurement costs, and improve production efficiency to achieve cost reduction and efficiency improvement [29] Smart Sensor Industry - The intelligent sensor industry is expected to expand due to policies and market demand The company's intelligent sensor products are mainly used in the automotive, home appliance, and low - altitude economy fields, and have entered the supply chains of many automotive companies [31] M & A Plan - The company will focus on investment and M & A opportunities in the intelligent sensor business to expand its scale and competitiveness [33]

Group 1: Research Basic Information - The research object is Bojie Co., Ltd., belonging to the special equipment industry, with a reception time of October 14, 2025, and the listed company's reception staff is the board secretary Huang Can [16] Group 2: Detailed Research Institutions - The research institutions include Fangzheng Huisheng (investment company, representative: Han Zhenguo), Yuanju Capital (others, representative: Yang Yan), Qianyi Capital (others, representative: Sun Linqi), Yangxiang Investment (others, representative: Dai Xi), Cinda Securities (securities company, representative: Wang Rui), E Fund (fund management company, representative: Yao Huanchen), Grain Investment (others, representative: Guo Yuanrao), Saisuo Investment (others, representative: Huang Qixu), Roadshow Era (others, representatives: Wang Jizhuo, Lin Qian), Hongrui Zhiying (others, representative: Zhang Xianfu) [17] Group 3: Main Content - The company led investors to visit the production line and then returned to the meeting room for communication [22] - In the liquid - cooled server testing field, besides N customer's demand, other customers also want to introduce liquid - cooling and testing solutions, and the company will actively expand the market. The current target is to provide thermal management solutions for customers' high - power products [23] - Liquid - cooled components are the company's future development direction and are still in progress. The self - developed liquid - cooled module products are used in the company's testing equipment. The company cooperates with the industrial chain and universities to research and develop materials needed for liquid - cooling solutions but does not produce the materials itself [23][24] - The company focuses on water - cooling heads, quick connectors, etc. in the liquid - cooling field. It will design, develop, and integrate industrial chain resources based on its competitive advantages and customer needs to achieve the launch and mass production of component products [25] - The core advantage of the company's transformation from the testing field to component supply is its high - quality customer resources. Through in - depth cooperation with customers in the testing field, it can accurately capture customer pain points and provide solutions [25] - The big data and cloud server testing field accounts for about 25% of the company's revenue [26] - Based on the needs of N customer and other customers, the orders for AI server - related testing equipment are expected to be optimistic this year. The orders for automotive electronics are growing rapidly and have been delivered. The orders in the 3C field are relatively stable. The orders for MLCC field equipment are growing rapidly as the MLCC industry has recovered since last year. The revenue of dicing machines in the semiconductor field is growing rapidly but with a small overall proportion [27]

Group 1: Research Basic Information - Research object: Pulead [17] - Industry: Not specified [17] - Reception time: October 14, 2025 [17] - Listed company reception personnel: Deputy General Manager and Secretary of the Board, Guo Kangli [17] Group 2: Detailed Research Institutions - Reception object: Caitong Securities, Zhonggeng Fund [18] - Reception object type: Securities company, Fund management company [18] - Institution - related personnel: Xing Hanwen, Xiong Zhenghuan [18] Group 3: Main Content Company's self - developed battery pack - The purpose of self - developing lithium - ion battery packs is to form a battery pack platform and empower the production and sales of complete machines. The group has become a partner of ALDI in the power tool field, providing 12V, 18V platform series products and solutions to improve product coverage and brand influence in the European market [23] Acquisition of BATAVIA B.V. - In October 2023, the company acquired BATAVIA B.V. to form a synergy among R & D, production, and marketing channels, and it has become a strategic fulcrum in the group's global layout [23] Product proportion - In 2024, the revenue proportion of electrothermal products was about 25%, spraying products about 28%, blowing and suction products about 14%, and the rest were other products [23] Product grade extension - The company is extending products from general - grade to professional and industrial - grade fields. The hot air gun has bridged general - grade and professional - grade, and other categories like nail guns and spraying products have launched relevant professional and industrial - grade products [24] Employee equity incentive - In August 2024, the company completed share repurchase, using about 50 million yuan to repurchase more than 2 million shares, which will be used for employee stock ownership or equity incentive plans within the legal time limit [24]